Erratum
for
Stephenson et al., J Clin Oncol 25 (15) 2035-2041.
Journal of Clinical Oncology, Vol 25, No 26 (September 10), 2007: pp. 4153
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.13.6291
ERRATUM
The May 20, 2007, article by Stephenson et al entitled, "Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy" (J Clin Oncol 25:2035-2041, 2007) contained an error. In Figure 3A, the neoadjuvant androgen-deprivation therapy scale should have shown that this therapy is associated with improved prostate-specific antigen control, as indicated in the text. The corrected Figure 3 is reprinted below in its entirety.
View larger version (15K):
[in this window]
[in a new window]
[PowerPoint Slide for Teaching]
|
Fig 3. (A) Pretreatment nomogram predicting 6-year progression-free probability after salvage radiotherapy for prostate-specific antigen (PSA) recurrence after radical prostatectomy. (B) Calibration of the nomogram. Dashed line indicates reference line where an ideal nomogram would lie. Solid line indicates the performance of the current nomogram. Dots are quartiles of our data set. Instructions: Locate the patient's Gleason score on the respective axis. Draw a straight line up to the Points axis to determine how many points toward disease recurrence that the patient receives for his or her Gleason score. Repeat this process for the other 10 disease and treatment parameters. Sum the points and locate this number on the Total Points axis. Draw a straight line down to find the patient's probability of remaining free of disease progression at 6 years after salvage radiotherapy, provided the patient does not die of another cause first.
|
|
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
|
